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INTRODUCTION
Doxorubicin which belongs to the anthracycline family of drugs ,is a key component of 
chemotherapy regimens and is  the most  active  agent  for  the treatment  of  lymphoma. 
However  doxorubicin  use  is  limited  by  its  severe  cardiotoxicity,  including 
cardiomyopathy and congestive cardiac failure,  which are late cardiac effects usually 
occurring  after  doses  greater  than  550  mg/m2 (1).Early  toxicity  is  rare  and  includes 
myocarditis,  pericarditis  and  arrhythmias  .Late  cardiotoxicity  after  doxorubicin  has 
largely been studied in children (2,3) but less often in adults. In children, the prinicipal risk 
factor for anthracycline cardiomyopathy is highly dependant on cumulative doses (1-4). For 
adults few studies have been performed in the setting of breast cancer with epirubicin (5) or 
doxorubicin  (6),of  acute  myeloid  leukaemia  after  idarubicin  (7)or  after  doxorubicin  for 
various hematologic malignancies (8,9).For these patients, an increased risk of developing 
late cardiotoxicity after anthracycline treatment has been associated with advancing age 
or with higher cumulative doses (4,9).Most of these studies involved patients who received 
doxorubicin ranging from 450-550 mg/m2. Altough risk factors for doxorubicin –induced 
congestive heart failure have been studied ,subclinical cardiac toxicity after lower doses of 
doxorubicin is less usnderstood .
Therefore we studied the occurrence of late cardiac abnormalities by measuring systolic 
function,  Left  Ventricular  Ejection  Fraction  (LVEF),  Fractional  shortening  (FS)  in 
patients treated with doxorubicin for lymphoma .We evaluated the cardiac function  of 
patients observed for atleast 5 years after successful treatment of the lymphoma  with 
chemotherapy regimens including doxorubicin .
AIMS OF THE STUDY
1. To assess the cardiac status of long term survivors who previously received doxorubicin- 
based chemotherapy for lymphoma .
2. To analyze the risk factors for development of late anthracycline cardiotoxicity.
REVIEW OF LITERATURE
1 DEFINITION & NATURAL HISTORY OF ANTHRACYCLINE 
CARDIOTOXICITY
Anthracycline induced cardiotoxicity can be broadly classified by clinical presentation 
into  three  categories  :  acute,  early  onset  chronic  cardiomyopathy  and  late  onset 
cardiomyopathy.They  differ  not  only  in  their  time  of  presentation  but  also  in  their 
clinical characteristics and their association with risk factors known to predispose to 
anthracycline induced cardiotoxicity
1.1 Acute anthracycline induced cardiotoxicity
Acute  anthracycline  induced  cardiotoxicity  is  defined  as  a  reversible  depression  of 
myocardial function after the initial infusion of anthracycline. With current protocols 
this type of toxicity is rare, occurring in <1 % of patients.The clinical manifestation may 
occur within the first week and is usually an acute but transient decrease in contractility 
occasionally  resulting  in  congestive  cardiac  failure(14,15).  Much  less  frequently  seen 
complications  include  myocarditis  –pericarditis  syndrome  and  acute  life  threatening 
cardiac arrhythmias, such as ventricular or supraventricular tachycardias(17-18). Altough 
extremely  rare,  myocardial  ischemia  and  infarction  or  sudden  death  as  a  result  of 
coronary vasospasm have been reported in the first hours of therapy .
1.2 Early onset chronic progressive anthracycline induced cardiotoxicity
Usually  presents  within 1 year   after  the completion of  anthracycline treatment,  has 
known risk factors and will persist or progress even after discontinuation of therapy. The 
majority of adult patients who develop significant cardiotoxicity have a chronic dilated 
cardiomyopathy .In the pediatric patient,  however, the clinical picture is  as likely to 
become that of a restrictive cardiomyopathy on increasing follow up. This distinction is 
important, as it has implications not only for diagnosis but also for treatment .
1.3 Late onset chronic progressive cardiomyopathy
Defined as cardiomyopathy that manifests itself after a latency period of  more than one 
year after completion of anthracycline therapy .With this type of cardiotoxicity, there is 
a  period  during  which  no  left  ventricular  dysfunction  or  arrhythmias  are  detected, 
cardiac function appears normal, and patient is asymptomatic. After this latent period, 
there is progressive and rarely fatal deterioration in cardiac function .
2. PATHOGENESIS
Several mechanisms have been suggested to explain the pathogenesis of anthracycline 
induced cardiotoxicity .In most cases more than one mechanism is probably involved 
2.1 Cellular level
The most frequently proposed mechanism at the cellular level involves the mediation by 
oxygen radicals  (26-34).There is  growing evidence that the mitochondria of the cardiac 
myocyte  may  play  an  important  role  in  anthracycline  induced 
cardiomyopathy.Anthracyclines  are  metabolised  into  aglycones,  the  noncarbohydrate 
portion of a glycoside. Interaction of these aglycones with the mitochondrial membrane 
generates superoxide and superhydroxide free radicals and increase the permeability of 
the mitochondrial membrane. Because the myocardium is naturally poor in the catalytic 
enzymes  that  break  down  these  free  radicals,  the  radicals  accumulate,  eventually 
destroying  the  mitochondria  .New drugs  such  as  dexrazoxane  and  probucol,  act  to 
reduce  the  formation  of  these  free  radicals  and  have  successfully  prevented 
anthracycline induced cardiotoxicity in both animal  and human studies  (32,34-40). Other 
hypothesis proposed in literature include myocyte damage from calcium overload (41-45), 
cellular  toxicity  from  metabolities  of  doxorubicin  other  than  aglycones  (46,47), 
disturbances in myocardial adrenergic function (48-50), release of vasoactive amines (51-52) 
and elaboration of pro inflammatory cytokines (53-56)
2.2 Mechanistic level
The  mechanistic  changes  seen  are  now  better  understood  with  the  application  of 
improved & more sophisticated echocardiographic techniques. For both early & late – 
onset  types  of  chronic  progressive  anthracycline  –induced  cardiomyopathy,  the 
mechanisms appear to differ for children and adults.
2.2.1 Adult versus pediatric patients
Anthracycline –associated cardiotoxicity in patients treated in adulthood has generally 
been described as a form of dilated cardiomyopathy, in which chronic damage to the 
myocardium results in a dilated poorly contractile heart. The wall of the ventricle thins 
and there is more stress on the heart. However a recent study of patients who received 
anthracyclines during childhood revealed a different pattern of myocardial damage, with 
decreased ventricular compliance  (57). There was an overall decrease in left ventricular 
dimension in relation to body surface area. This is the pattern observed in restrictive 
cardiomyopathy, in which the ventricle loses its ability to dilate. Echocardiographic and 
clinical findings suggest that the medium to long term course in anthracycline treated 
children may be characterised by progression of a restrictive cardiomyopathic process, 
resulting in a small thin left ventricle relative to body surface area. The reason for the 
difference in presentation between patients  treated in childhood and those treated as 
adults is unknown, but it may be related to ongoing somatic growth in children. By 6 
months of age, the heart has the adult number of myocytes & subsequent myocardial 
growth occurs primarily by hypertrophy of individual myocytes. In young children, it 
appears that anthracycline cause a dose related impairment of myocardial growth. Long 
term follow up studies of these patients suggest that even after cessation of therapy, 
there may be an ongoing loss of myocardial cells. The myocardial growth failure, loss of 
myocardial cells, or both may contribute to the striking decrease in left ventricular mass 
in some of these patients (58,59)
3 RISK  FACTORS  FOR  ANTHRACYCLINE  –INDUCED  
CARDIOTOXICITY 
In  the  last  10  years,  major  progress  has  been  made  in  identifying  risk  factors  for 
anthracycline –induced cardiotoxicity. These risk factors relate to early and late but not 
acute  cardiotoxicity.  Risk  factors  for  anthracycline  –  induced  cardiotoxicity  in 
decreasing order of importance (134)
3.1 Cumulative dose
Total  cumulative  anthracycline  dose  is  well  established  as  a  risk  factor  for  cardiac 
damage. In a study examining the late cardiac effects of doxorubicin therapy in children 
with ALL, 57% of the patients had abnormalities of left ventricular function and the 
cumulative  dose  of  doxorubicin  was  the  most  significant  predictor  of  abnormal  
function  (p<0.02)(58).In  a  recent  study  of  6493  children  who  received  anthracycline 
treatment,  patients who received >550 mg/m2  of anthracycline were five times more 
likely  to  have  early  cardiotoxicity  than  those  who  received  lower  cumulative  doses 
(60).Despite a wide variation in patient sensitivity to anthracyclines, for most adults a total 
cumulative dose under 400-450 mg/m2 is likely to result in chronic cardiotoxicity. To 
put the role anthracycline dosage in proper perspective, it is important to remember that 
a dose of anthracycline that does not result in late cardiac abnormalities has not been 
established. Altough cumulative doses in excess of 1000 mg/m2 have been well tolerated 
by some patients  (61,62), there are reports of cardiac dysfunction in patients treated with 
less than 300 mg/m2(63,64). No safe dose of anthracycline has been established .
3.2 Rate of anthracycline administration 
There is evidence to suggest that the rate of anthracycline administration (continuous 
infusion  versus  bolus  doses  )has  an  effect  on  the  relative  risk  of  developing 
cardiotoxicity during or following treatment. This relative risk may differ significantly 
for adults & children. Lipshultz et al  suggest that for pediatric patients ,even when the 
cumulative dose is limited, higher dose rates are an important predictor of impairment of 
left ventricular dysfunction years after treatment. Some investigators have suggested that 
anthracycline  morbidity  in  adults  can  be  reduced  by  use  of  prolonged  intravenous 
infusions in place of bolus therapy(65,66).At equal doses .a longer time of infusion lowers 
the  peak  anthracycline  blood  level.  In  a  survey  of  1273  patients  who had  received 
doxorubicin,  none  of  182  patients  who  received  slow  infusions  developed 
cardiomyopathy as compared to 2% of the patients who were treated with bolus doses (8). 
In another study, a maximum single dose of >50 mg/m2 was associated with a risk of 
cardiotoxicity 2.81 times greater than risk of cardiotoxicity associated with a lower dose 
(60).
However a recent  study by Lipshultz et  al  showed cardiac Troponin T elevations in 
patients who received doxorubicin by either continuous or bolus infusion, suggesting 
that  cardiac  damage  was  not  prevented  by  lower  peak  concentrations  in  continuous 
infusion (67).
3.3 Age 
Children appear to be more vulnerable to anthracycline –induced myocardial impairment 
(68,69). An age of <4 years at the time of exposure has been shown to be a risk factor for 
abnormal  cardiac  function  
(p<0.003)(58). In another study of 120 children and adults who had received cumulative 
doses of 244-550 mg/m2 of doxorubicin ,younger age at diagnosis was associated with 
and predictive of ventricular dysfunction 
3.4 Length of follow up 
With longer follow up after completion of anthracycline therapy, the prevalence and 
severity of cardiac abnormalities increase(70). This is presumed to be related to the new 
cases of late - onset cardiac toxicity and worsening of previously detected early onset 
chronic progressive cardiomyopathy. The importance of longer follow up has only now 
become apparent, with the increasing numbers of asymptomatic cancer survivors at risk 
for cardiac dysfunction later in life.
3.5 Gender
Female  patients  appear  to  be  vulnerable  to  the  cardiotoxic  effects  of 
anthracyclines(60,71-74).  In a study of patients treated with anthracyclines, for childhood 
cancers, female patients had significantly greater reduction in ventricular contractility, 
regardless  of  diagnosis.  Similarly  the  higher  the  cumulative  dose  of  anthracycline 
received,  the  greater  was  the  difference  in  contractility  between  male  and  female 
patients. Altough the reason for this is not understood, differences in body composition 
between the two sexes may play  a role by altering the distribution and metabolism of 
anthracycline(75,76).  Since  girls  have  more  body  fat  than  boys  for  comparable  body 
surface area and doxorubicin is reduced with increased body fat (77), equivalent doses of 
doxorubicin  in  girls  could  lead  to  higher  concentrations,  for  a  longer  time,  in  non 
adipose tissue, including the heart
3.6 Concomitant mantle radiation 
Radiation  therapy  is  frequently  used  in  combination  with  multidrug  chemotherapy 
regimens in the treatment of patients with various hematologic cancers and solid tumors. 
Altough it  is widely accepted that concomitant exposure of the mantle radiation and 
anthracycline enchances the risk of cardiotoxicity, the evidence, though suggestive is not 
conclusive.  Proga  et  al   evaluated  the  histologic  features  of  endomyocardial  biopsy 
specimens obtained from 12 patients who had received mediastinum radiation before 
anthracycline therapy and compared them with those of patients who had not received 
mediastinum radiation .They found a significantly higher  severity of histopathologic 
changes in the patients pretreated with radiation (p<0.01).There are other reports in the 
literature  that  suggest  radiation  exposure  enchances   the  cardiotoxic  effects  of 
anthracyclines(78,79). Most of these however remain anecdotal.
4 DETECTION & MONITORING 
Long  term  cardiac  monitoring  performed  locally  for  individual  patient  care  but 
remeasured  in  a  standardised  manner  is  needed  after  exposure  of  any  patient  to 
anthracyclines. Cardiac risks and need for long term monitoring should be explained to 
patients  before  administration  of  anthracyclines.  The  education  of  primary  care 
physicians,  oncologists and cardiologists who care for  survivors of childhood cancer 
regarding the late effects and their importance is essential to providing appropriate care 
to these patients.
A multidisciplinary approach with expertise  in Oncology,  Cardiology and quality  of 
care,  among  others  will  be  needed  to  understand  true  impact  of  cardiovascular 
abnormalities in long term survivors of cancer in childhood. Pregnant women, patients 
on growth hormones, competitive athletes may need closer monitoring, as many patients 
present with symptoms potentially cardiac in nature such as syncope, chest pain. 
Many patients with mild to moderate left ventricular dysfunction may have no signs or 
symptoms  of  congestive  cardiac  failure  and  regular  physical  examinations  are 
inadequate to detect anthracycline cardiotoxicity. However regular cardiac monitoring 
studies during treatment for cancer in paediatric patients may not necessarily predict 
which patient will be at risk of developing late cardiac dysfunction (103)
4.1 Echocardiography
A complete echocardiography examination with two Dimensional, M mode and colour 
Doppler  examination  is  the  most  commonly  used  method  for  examining  ventricular 
function. Fractional shortening and ejection fraction are the most common indices used 
to assess left ventricular systolic functions. These indices are load dependent (104). Pre-
load is the degree of diastolic filling of the ventricle.  As the pre-load increases,  the 
stroke volume and cardiac output increase. After-load is defined as the tension on the 
ventricular wall at the end of systole and is an indirect measure of the resistance the 
ventricle has to overcome to eject blood. Pre-load and after-load are frequently altered 
during chemotherapy and therefore need to be taken into consideration in the evaluation 
of each patient. 
In general, echocardiography is a less invasive and more sensitive method of detecting 
abnormalities of left ventricular structure and function than other methods. In addition to 
providing  anatomic  details  and  measurements  of  chamber  sizes  and  wall  thickness, 
echocardiography enables the assessment of the relationship between the rate corrected 
velocity of fibre shortening and the end systolic wall stress, a reliable load independent 
measure of  cardiac  contractility  that  can be  followed during and after  anthracycline 
therapy(58).
4.2 Contrast radionuclide angiography:
In  anthracycline  induced  cardiomyopathy,  the  left  ventricular  ejection  fraction  as 
measured  with  radionuclide  angiography correlates  with  the  severity  of  pathological 
changes  seen  on  endomyocardial  biopsy(105).  It  has  very  good  specificity  (75%)  for 
detecting patients at moderate to high risk of developing Congestive cardiac failure after 
anthracycline therapy. There are however some distinct limitations to this method. First, 
radionuclide angiography measures the ejection fraction which is a load dependent index 
of  systolic  function.  In  addition,  it  is  a  semi-invasive  and  moderately  expensive 
procedure. The lack of a reproducible ejection fraction can lead to false-positive and 
false-negative  results.  Therefore,  these  studies  should  only  be  performed  in  well 
established,  reliable  nuclear  medicine  centres(65).  The  usefulness  of  radionuclide 
radiographic measurement of left ventricular ejection fraction is often restricted to the 
older child or adult in whom echocardiographic windows are limited as in obesity or 
emphysema.  The  radiation  exposure  especially  with  repeated  examinations,  may  be 
significant and may hinder its use for long term cardiac surveillance in some patients.
4.3 Endomyocardial Biopsy (EMB):
The  value  of  EMB  in  assessing  anthracycline  cardiotoxicity  has  been  questioned 
because the data is contradictory. In some studies, histologic examination of an EMB 
specimen is a moderately sensitive test in adults for the effects of anthracyclines (106,107), 
shows a linear correlation with cardiotoxicity and is predictive of onset of early cardiac 
failure(108).  Yet, in other studies abnormailities were seen in biopsies of most patients 
who had received as little as 200 mg/m2 of doxorubicin and the extent of abnormalities 
roughly correlated with the dose.  However,  the abnormalities  were seen well  before 
symptoms  occurred  and  in  fact  were  seen  in  many  patients  who  did  not  develop 
symptoms after  extended follow-up.  In  addition,  other  patients  whose biopsy  results 
were normal subsequently developed congestive heart failure (107).
EMB surveillance has many limitations. In addition to being invasive, it may involve a 
higher risk of complications in patients with cancer, who may already be at increased 
risk for excessive bleeding, infection and impaired wound healing (110). Sampling error is 
highly possible as only the apical portion of the right ventricular septum is sampled. 
Since the left ventricle (65) is not sampled, the relevance of the results to left ventricular 
dysfunction may be limited.  Currently, this method of monitoring is not feasible for 
many children or even for most adults. 
4.4 Electrocardiogram:
The 12-lead electrocardiogram (ECG) is readily available and non-invasive. However, it 
lacks  sensitivity  for  anthracycline  related  cardiotoxicity  and  does  not  measure  LV 
function. It is useful for detecting ventricular hypertrophy and arrhythmias that may be 
seen  in  anthracycline  cardiotoxicity.  A  study  of  56  anthracycline  treated  long  term 
survivors of cancer suggested that prolonged QTc interval of the ECG may be useful in 
the timely detection of cardiotoxicity and progressive change in cardiac health. Even 
here, the changes are not specific for anthracycline induced cardiotoxicity. There is a 
very low correlation between ECG changes and the morphologic or clinical findings of 
anthracycline cardiomyopathy (111-113)
4.5 Chest X-ray:
Though familiar, non-invasive and readily available, the chest X-ray is not sensitive or 
specific  and  is  usually  not  helpful  in  the  early  stages  of  anthracycline  induced 
cardiomyopathy.  In  the  late  stages,  after  the  onset  of  congestive  heart  faiure,  non-
specific cardiomegaly or pulmonary oedema may be apparent, as in congestive heart 
failure from any cause. 
4.6 Biochemical markers of myocardial injury:
Biochemical markers may be useful for the detection of acute myocardial damage as a 
result of anthracycline therapy. A recent study evaluated cardiac troponin – T(cTnT) 
blood  levels  in  51  consecutive  patients  who  received  doxorubicin  for  ALL,  cTnT 
elevations were observed(67). These results suggest elevation of blood cardiac troponin T 
in children relates to the severity of myocardial damage. In addition, the magnitude of 
elevation in the anthracycline treated patients predicted left ventricular dilatation and 
wall  thinning  9  months  later,  suggesting  that  serum  cTnT  elevations  may  predict 
subsequent sub-clinical and clinical cardiac morbidity and mortality (67).
Measurement  of  cTnT  is  more  sensitive  than  measurement  of  creatine  kinase  MB 
fraction for the assessment of acute anthracycline induced cardiotoxicity(67). However, 
larger controlled trials are necessary to determine the sensitivity and applicability of 
these studies to the general adult and pediatric population.
5 TREATMENT
Despite the improved understanding of the changes occurring in the heart affected by 
anthracycline  induced  cardiotoxicity,  appropriate  rational  therapeutic  interventions 
remain  difficult(12).  Current  management  modalities  concentrate  not  only  on 
symptomatic  relief  when  symptoms  occur,  but  also  on  correcting  the  underlying 
abnormalities, such as increased after-load and decreased contractility using after-load 
reducing and inotropic drugs.
5.1 After-load reduction:
After-load reduction with angiotensin converting enzyme inhibitors such as enalapril or 
captopril  may  be  indicated  in  patients  with  elevated  after-load  and  pre-clinical  LV 
dysfunction diagnosed by echocardiogram. Although the consensus suggest that after-
load reduction therapy should be initiated when after-load is elevated and contractility is 
impaired or when symptoms appear, there is not a proven role for preventive use of 
these medications, even when the patient is at apparently higher risk. With increased use 
of these drugs in children, they appear to be effective and safe even in young children 
when used appropriately  and with close monitoring.  There are  reports  of  short-term 
improvement  after  the  use  of  enalapril  in  asymptomatic  patients  proven  by 
echocardiography  to  have  anthracycline  induced  dilated  cardiomyopathy(115) but  the 
results of prospective, randomized, placebo-controlled studies are currently lacking.
5.2 Management of heart failure:
Once  symptoms  of  dysfunction  occur,  the  decision  to  treat  is  easier.  Treatment 
encompassing  after-load  reduction,  diuresis  and  digoxin  is  standard  for  CCF, 
irrespective of the cause.
5.3 Transplantation:
With  end-stage  cardiac  failure  secondary  to  anthracycline  induced  cardiomyopathy, 
transplantation  remains  a  viable  option.  For  patients  with  significant  restrictive 
cardiomyopathy, the failure to respond to diuretics, after-load reduction has resulted in 
the early listing for heart transplantation in this population to avoid the need for heart-
lung  transplantation.  Reports  suggest  that  treatment  for  cancer  should  not  preclude 
cardiac  transplantation  when  it  is  necessary(116,117).  The  limited  availability  of  donor 
hearts remains a problem for all patients awaiting organ transplantation.
6. PREVENTION
The primary goal in prevention, which is to identify the strategies that will maximize 
oncologic  efficacy  while  minimizing  cardiac  toxicities  is  not  disputed.  Validated 
strategies  for  detection  and  prevention  of  anthracycline  induced  cardiomyopathy 
however needs to be established. As the magnitude of the problem of cardiotoxicity in 
this patient population has become increasingly apparent over the last  few years, the 
need for larger control studies to address this issue has become ever more urgent.
6.1 Limitation of cumulative dose:
The arbitrary magnitude of limitation of anthracycline dose is especially contentious and 
has  been  debated.  To  reiterate  there  is  no  safe  dose  of  anthracycline  at  which  no 
cardiotoxicity  is  seen.  Therefore,  reduction  of  cumulative  anthracycline  therapy  is 
appropriate  only  when  the  minimized  cumulative  dose  allows  effective  anti-tumor 
activity  and the  overall  morbidity  and mortality  are  reduced by this  decision .Some 
authors have recommended a more cautious approach, with the anthracycline dose being 
reduced when any tests suggest cardiac injury (118). This assumes that any abnormality or 
significant  change in test  results  is  due to  anthracyclines.  The available  data  do not 
justify  adoption  of  this  recommendation.  Altough  a  reduction  in  anthracycline  dose 
based on the sub clinical evidence of toxicity may seem reasonable, several factors must 
be considered .
• None of the methods of screening for anthracycline cardiotoxicity has been shown 
to be adequately predictive of early or late cardiac outcomes 
• High cumulative doses of anthracyclines are intended to result in high cure rates 
.If the reduction in anthracycline dose increases the death rate from cancer more 
than it decreases morbidity and  mortality from heart failure, then patients will  be 
ill served .Most patients would accept some impairment of cardiac function if the 
potential  for  oncologic  cure  were  improved.  Minor  abnormalities  of  cardiac 
function  would  almost  certainly  represent  an  acceptable  outcome,  whereas 
disabling symptoms, early or late congestive heart failure or cardiac death would 
not.
• There are no adequately controlled, definitive studies demonstrating the efficacy 
of a dose reduction technique 
6.2 Accounting for age and gender 
Another preventive measure would account for age and sex in designing anthracycline 
treatment protocols. However, we must again employ caution and ensure that adequate 
doses  of  chemotherapy  are  provided  for  each  patient.  To  do  this  properly,  larger 
controlled  trials  are  needed  to  provide  appropriate  guidelines  for  tailoring  a 
chemotherapeutic regimen.
6.3 Continuous versus bolus infusion:
There is a suggestion that the use of prolonged intravenous infusions instead of bolus 
doses of anthracyclines may reduce the risk of cardiotoxicity, perhaps by lowering peak 
blood levels of anthracyclines(65,66). Clinicians should be cautious when considering this 
recommendation. The study discussed earlier, that showed an apparent reduction in the 
incidence  of  anthracycline-induced  cardiomyopathy,  was  based  on  182  patients,  all 
adults,  who  received  prolonged  infusions(8).  In  children  with  ongoing  myocardial 
growth,  concerns  remain  about  potential  risks  of  the  longer  anthracycline  exposure 
period entailed in  continuous infusions as  a risk for  less  recovery of  cardiomyocyte 
damage by anthracycline chemotherapy.
6.4 Cardioprotectants
Concurrent administration of cardioprotectants such as dexrazoxane and probucol has 
been suggested for prevention of anthracycline cardiotoxicity. Both dexrazoxane (ICRF 
187)  and  probucol  are  antioxidants  that  are  still  investigated  for  their  efficacy, 
limitations and potential risks.
6.4.1 Dexrazoxane
The specific mechanism of the cardioprotective effect of dextrazoxane is unknown(12); it 
appears to prevent  free radical formation(119-124).  Significant  cardioprotection has been 
demonstrated in  animal  models(35),  adult  humans(36,37,39,40) and more recently,  in small 
number of children(38). It is currently approved for clinical use in women with metastatic 
breast cancer after a cumulative anthracycline dose of 300 mg/m2.
Many questions remain to be answered about the efficacy and safety of dexrazoxane as a 
cardioprotectant.  There is  still  a  need for conclusive evidence that  it  reduces overall 
morbidity  and mortality  in  children with cancer,  as  it  is  unclear  whether  the use of 
dexrazoxane  will  be  associated  with  reduced  late-onset  progressive  cardiomyopathy. 
The mechanism of the potentially beneficial effects on the health of the myocardium is 
also  unclear,  and  the  effect  of  dexrazoxane  on  the  response  of  most  cancers  to 
chemotherapy  is  currently  unknown.  There  is  some  concern  that  dexrazoxane  may 
interfere with the anti-tumour efficacy of anthracyclines(125). In fact, lower response rates 
and faster anti-tumour progression times have been seen in patients with early breast 
cancer treated with dexrazoxane(21,126). There is a concern that dexrazoxane may increase 
bone  marrow  depression,  and  both  anthracyclines(127) and  agents  related  to 
dexrazoxane(128) are potential risk factors for late recurrent or second malignancies.
6.5 Other strategies
Liposomal  anthracyclines  are  now  in  phase  II  clinical  trials,  and  the  anthracycline 
structural  analogs,  such as mitoxantrone and idarubicin,  which are known to be less 
cardiotoxic, have been considered as alternatives to anthracycline therapy. Their anti-
tumour properties however appear to be less effective.
Beta-adrenergic  blocking  agents  have  been  shown  to  reduce  anthracycline  induced 
cardiotoxicity(129) and prevent anthracycline induced intracellular calcium overload(130). 
Calcium  antagonist  such  as  prenylamine  have  been  studied  for  their  efficacy  in 
cardioprotection.  While  a  pilot  study  suggested  prenylamine  may  provide  some 
cardioprotection in humans(131),  animal studies have demonstrated both enhanced and 
reduced anthracycline cardiotoxicity with the use of calcium antagonist(129,132). The use of 
treatment such as intravenous immunoglobulins may reduce myocyte destruction and 
promote myocyte recovery(12).
7 CONCLUSION
Prevention  of  late  cardiac  dysfunction,  especially  late  onset  chronic  progressive 
cardiomyopathy, is a priority for all patients and for their caregivers. Although many 
long term survivors of childhood cancer have asymptomatic persistent or progressive 
elevation  of  afterload  with  normal  contractility  5-15  years  after  anthracycline 
chemotherapy, the real question remains what the condition of these patients will be in 
another 10, 20, 30, or more years(12). We need protocol based cardiac follow-up of these 
patients to determine 
1. Whether one protocol or intervention during treatment is better than another.
2. What the natural course of cardiotoxicity is.
3. What the risk factors for cardiotoxicity are.
4.  Whether  monitoring  and  dose  modifications  as  currently  practiced  by  some 
cancer centres improve survival.
Prevention  is  the  future  of  minimizing  anthracycline  induced  cardiotoxicity.  It  is 
important  that  all  primary  care  providers  be  aware  of  the  increasing  numbers  of 
asymptomatic cancer survivors at risk for cardiac dysfunction later in life. If the risk 
factors such as high cumulative doses of anthracycline treatment, young age the time of 
exposure to anthracyclines, concurrent mediastinal radiotherapy, or any of the other risk 
factors introduced above are identified early, we may be able to minimize the adverse 
cardiac effects of anthracycline treatment. 
SUBJECTS AND METHODS
All patients with a diagnosis of Non–Hodgkin’s lymphoma or Hodgkin’s lymphoma 
treated at Cancer Institute, Adyar, Chennai with atleast 5 years of follow up reporting to 
Out Patient Department were eligible. Patients had to be in complete remission after 
chemotherapy.
Inclusion criteria
1. Histological confirmation of lymphoma.
2. Baseline cardiac evaluation EF>50%
3. Last administration of anthracyclines at least 5 years back
4. Any age/gender.
Exclusion criteria
1. Non anthracycline based chemotherapy .
2. Active cardiac disease such as CHF or arrhythmias 
After  eligibility  was  determined,  informed  consent  was  obtained  from  all  patients. 
Cardiac evaluation consisted of physical examination, Electrocardiogram, Chest x-ray 
and Echocardiography.
Echocardiographic Evaluation 
Echocardiograms were analysed by a cardiologist who was unaware of each patient’s 
treatment protocol, cumulative doses of anthracyclines, and potential risk factors. Each 
patient  has  been  evaluated  at  least  5  years  after  the  end  of  the  last  course  of 
anthracycline by  the  cardiologist .The echocardiographic evaluation consisted of two 
Dimensional echocardiography and Doppler cardiography for the qualitative assessment 
of left ventricular regional wall motion, left ventricular end diastolic(LVED) and end 
systolic dimensions(LVES), ejection fraction(EF) were measured. Fractional Shortening 
(FS)  was  calculated  with  formula  LVED-LVES/LVED.  Echocardiography  was 
considered abnormal if FS was below 25%, EF was below 50%, (measured in M-mode 
or by 2D echocardiography) and abnormal wall motion such as dyskinesis, hypokinesis, 
or akinesis were found.
Electrocardiographic Evaluation 
The  electrocardiogram  (ECG)  findings  associated  with  anthracycline  cardiac 
dysfunction include sinus tachycardia, low voltage, poor R wave progression, and non-
specific T-wave changes. Even sinus tachycardia alone is a relatively late finding, such 
that serial ECGs are of little value in early detection (135).
CHARACTERISATION OF CLINICAL & SUBCLINICAL ANTHRACYCLINE- 
INDUCED CARDIOMYOPATHY (134)
Criteria Clinical 
Cardiomyopathy
Subclinical 
Cardiomyopathy–
decreased FS<25%
Clinical symptoms/
signs
Dyspnea on exertion 
Decreased exercise 
tolerance
Tachycardia
Pulmonary edema
Hepatomegaly
Gallop rhythms
Absence of clinical 
symptoms 
Chest x-ray Cardiomegaly
Pulmonary edema
Pleural effusions
No radiologic 
abnormalities
Echocardiography LVEF 50 % 
accompanied with 
clinical symptoms
FS<25%
Negative signs Absence of other causes 
of cardiomyopathy
Absence of other causes 
of cardiomyopathy
Statistical Analysis
The statistical analysis has explored the role of potential risk factors for the development 
of late cardiomyopathy. The role of each risk factor was studied by concomitant analysis 
of an FS lower than 25% which is the most reproducible parameter of left ventricular 
systolic function .
Seven  variables  were  studied  for  their  role  in  development  of  doxorubicin 
cardiomyopathy: age, sex, cumulative doses of doxorubicin, mediastinal radiotherapy, 
diabetes, Hypertension and years of follow up. 
Descriptive statistical  analysis  has been carried out  in  the present  study.  Results  on 
continuous  measurements  are  presented  on  Mean  ± SD  (Min-Max)  and  results  on 
categorical measurements are presented in Number (%). Significance is assessed at 5 % 
level of significance. Binomial proportion test has been used to find the significance of 
incidence cardiotoxicity in relation to the age, gender, follow up period and dose. 
1. Z-test for a proportion (Binomial distribution)
Objective:  To  investigate  the  significance  of  the  difference  between  the  assumed 
proportion and the P0 and the observed proportion P
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2. 95% Confidence Interval
  P ± 1.96* SE(P),  Where SE(P) is the Standard error of proportion = P*Q/√n
3.Significant figures 
+ Suggestive significance 0.05<P<0.10
* Moderately significant  0.01<P ≤ 0.05
** Strongly significant     P≤0.01
Statistical software: The Statistical software namely SPSS 15.0, Stata 8.0, MedCalc 
9.0.1 and Systat 11.0 were used for the analysis of the data and Microsoft word and 
Excel have been used to generate graphs, tables etc
RESULTS
Characteristics of 141  patients 
Table 1: Age distribution according to gender
Age in 
years
Male Female Total
No % No % No %
Up to 10 25 21.7 7 26.9 32 22.7
11-20 23 20.0 1 3.8 24 17.0
21-30 22 19.1 5 19.2 27 19.1
31-40 15 13.0 5 19.2 20 14.2
41-50 23 20.0 5 19.2 28 19.8
>50 7 6.1 3 11.5 10 7.1
Total 115 100.0 26 100.0 141 100.0
Mean ±SD 27.30±16.72 29.12±18.55 27.64±17.02
Table 2: Distribution of  lymphoma
Type of lymphoma Number %
Hodgkin’s lymphoma 98 69.5
Non- Hodgkin’s 
lymphoma
43 30.5
Total 141 100.0
Table 3: Adriamycin dose distribution( mg/m2)
Adriamycin dose 
distribution( mg/m2)
Number %
101-150 4 2.8
151-200 11 7.8
201-250 53 37.6
251-300 67 47.5
>300 6 4.3
Total 141 100.0
Table 4: DM/Hypertension
DM/Hypertension Number %
DM 3 2.1
Hypertension 1 0.7
Total 141 100.0
Table 5: Follow up years
Follow up in years Number %
5-10 110 78.0
11-15 26 18.4
16-20 5 3.5
Total 141 100.0
Mean ± SD 7.78±3.59
Table 6: Type of Chemotherapy
Chemo Number %
ABVD 24 17.0
CHOP 43 30.5
Hybrid 74 52.5
Total 141 100.0
Table 7: Cardio toxicity
Cardiotoxicity Number %
Absent 107 75.9
Present 34 24.1
Total 141 100.0
Table 8:Correlation between Age and cardiotoxicity 
Age in 
years
Total 
number of 
patients
Number of 
patients with 
cardiotoxicity
% of patients 
with 
cardiotoxicity
P value
Up to 10 32 11 34.4 0.173
11-20 24 3 12.5 0.184
21-30 27 5 18.5 0.496
31-40 20 4 20.0 0.668
41-50 28 5 17.9 0.443
>50 10 6 60.0 0.008**
Total 141 34 24.1 -
Table 9.:Correlation between Gender and cardiotoxicity 
Gender
Total number 
of patients
Number of 
patients with 
cardiotoxicity
% of patients 
with 
cardiotoxicity
P value
Male 115 22 19.1 0.208
Female 26 12 46.2 0.008**
Total 141 34 24.1 -
Table 10: Correlation between Type of Lymphoma & cardiotoxicity
Type of 
lymphoma
Total 
number of 
patients
Number of 
patients with 
cardiotoxicity
% of patients 
with 
cardiotoxicity
P value
Hodgkin’s 
lymphoma
98 20 20.4 0.392
Non- 
Hodgkin’s 
lymphoma
43 14 32.6 0.193
Table 11.: Correlation between Cumulative doses of Adriamycin and cardiotoxicity 
Adriamycin 
dose 
( mg/m2)
Total 
number of 
patients
Number of 
patients with 
cardiotoxicity
% of patients 
with 
cardiotoxicity
P value
101-150 4 0 0.0 -
151-200 11 3 27.3 0.804
201-250 53 8 15.1 0.126
251-300 67 18 26.9 0.592
>300 6 5 83.3 <0.001**
Total 141 34 24.1 -
Table 12:Correlation between Years of follow up and cardiotoxicity 
Follow 
up 
years
Total number 
of patients
Number of 
patients with 
cardiotoxicity
% of patients 
with 
cardiotoxicity
P value
5-10 110 21 19.1 0.220
11-15 26 8 30.8 0.424
16-20 5 5 100.0 0.001**
Total 141 34 24.1 -
Table 13: Mediastinal Radiation and cardiotoxicity 
RT site
Total 
number 
of 
patients
(n=141)
Number of 
patients with 
cardiotoxicity
(n=34)
% of patients 
with 
cardiotoxicity
(24.1%)
P 
value
MEDIASTINUM 15 8 53.3 0.053+
CERVICAL 21 3 14.3 0.293
Figure 1:Adriamycin dose distribution 
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Figure 4:Correlation between Cumulative dose and cardiotoxicity 
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Figure 5:Correlation between Follow up and cardiotoxicity 
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Figure 6: Correlation between Gender and cardiotoxicity 
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BASELINE CHARACTERISTICS
141 consecutive patients who came for follow up at Cancer Institute, Adyar Chennai met 
eligibility  criteria  for  the  study.  All  the  patients  had  received  their  last  dose  of 
doxorubicin more than 5 years ago. 
Patients were in age groups 4-69 years. Mean age at diagnosis was 27 years. Majority 
were in age group 0-20 years (Table 1).
Majority of patients were male who constituted 81.6% (n-115) (Table 1)
Majority of patients in the study were diagnosed as Hodgkin’s Lymphoma constituted 
69.5% (n-98).(Table 2)
The total dose of Adriamycin ranged from 100-410 mg/m2. Majority of patients received 
adriamycin  in  range  of  251-300  mg/m2 who  constituted  47.5%  (n-67).  4.3%  (n-6) 
patients received adriamycin dose of >300 mg/m2. Of 6 patients who received >300 mg/
m2, 5 patients received 400 mg/m2 and 1 patient received 410 mg/m2.  (Table 3) (Figure 
1)
At the beginning of chemotherapy, 2.1 %(n-3) patients had Diabetes mellitus and 0.7%
(n-1) had Hypertension (Table 4)
Mean duration between diagnosis and follow up cardiac evaluation was 7.7 years. (Table 
5) (Figure 5)
Among  all  patients,  34  (24.1%)  patients  had  cardiomyopathy.  
(Table 7) (Figure 2)
a. Clinical Cardiomyopathy
Of  34  patients  with  cardiomyopathy,  only  2  (5.8%)  patients  had  developed 
cardiomyopathy with dyspnea on exertion (grade 2) and congestive cardiac failure with 
follow up of 16 and 12 years respectively. Echocardiography confirmed the decreased 
ventricular function (EF-44% and 45%) with global hypokinesia.
b. Subclinical cardiomyopathy.
Doxorubicin –induced left cardiac dysfunction with decreased FS (<25%) was found in 
32 (94%) patients. Cardiomyopathy was direct consequence of anthracycline treatment.
None of these patients had electrocardiography changes compatible with doxorubicin –
induced cardiomyopathy (flattening of T wave, Prolongation of the QT interval, loss of 
voltage of R wave) or any clinical features of cardiomyopathy (134).  
Analysis of risk factors and late cardiotoxicity
Older age appears to influence the development of left ventricular function .In this study 
patients above 50 years were prone for cardiotoxicity (p<008%). (Table 8) (figure 3)
Female gender showed correlation with cardiotoxicity with (p<0.008). (Table 9)
Significant correlation was seen between higher cumulative doses of anthracyclines and 
left  ventricular  dysfunction  with  (p<001).  
(Table 11) (Figure 4)
Risk of cardiotoxicity increased with increasing number of follow up (p<0.001). (Table 
12). In our study patients with follow up of 16-20 had significant cardiotoxicity 
Mediastinal  Radiation  along  with  adriamycin  showed  suggestive  (p<0.053).  (Table 
13).Dose of anthracycline in patients with mediastinal radiation was between 210-300 
mg/m2. Radiation dose ranged from 3000-4000 cGy.
DISCUSSION
Echocardiography is the most widely used non-invasive evaluation of cardiac function 
and has been used largely to study anthracycline –induced cardiotoxicity, particularly in 
children.(17). Primary parameters of systolic function are represented by measurements of 
Left  ventricular  ejection  function(LVEF)  and  fractional  shortening  (FS);  however 
measurement of  LVEF is limited by a low sensitivity .Evaluation of FS has a higher 
sensitivity and specificity  (18,19) and there after,  had been chosen as the best  index to 
assess  systolic  function  after  anthracycline  treatment  in  routine  monitoring(18).In 
children, FS below 28% or a decrease of 10 percentile compared with initial values are 
criteria  of  systolic  dysfunction  (20,21).  Because  few studies  were performed in  adults, 
specific criteria of anthracycline cardiomyopathy are not defined precisely. According 
to  previous  studies  in  asymptomatic  left  ventricular  systolic   dysfunction  performed 
apart from the context of chemotherapy (22), we defined cardiomyopathy as a decrease of 
FS (<25%)and to increase specificity while preserving sensibility .we studied features of 
patients with decreased LVEF (<50%), decreased FS(25%) or abnormal function.
Among the 141 assessable survivors, 34 (24.1%) demonstrated decreased FS <25 %, 
Only  2  patients  developed  clinical  symptoms  of  doxorubicin  –induced  CHF  with 
ejection fraction 44-45 %. Thirty two patients demonstrated the presence of subclinical 
cardiomyopathy  (FS<25%) .Evaluation of Fractional shortening has a higher sensitivity 
and specificity & has been chosen as the best index to assess systolic function after 
anthracycline treatment in routine monitoring (18).
Comparable  rates  of  depressed  contractility  had  been  described in  adult  long –term 
survivors (range 14-37%) with a median cumulative doses of doxorubicin ranging from 
200-350 mg/m2(2,8,9,16).
In  pediatric  series  of  long  –term  survivors  previously  treated  with  comparable 
cumulative doses of doxorubicin ,the overall  incidence of systolic abnormalities was 
similar (2,21,23).
Even if no cardiac treatment is required for asymptomatic patients,an appropriate follow 
up is recommended because evolution of these complications is not known. (24)
In our series, older age (>50 years ) is a risk factor for development of doxorubicin –
induced cardiomyopathy which was confirmed by previous studies (4,9,11) .
Female sex also predicts left ventricular dysfunction in our series. In study by O. Hequet 
et  al(134),  male  sex   was  the  major  risk  factor  which  predicted  left  ventricular 
dysfunction .
Patients with Diabetes Mellitus (DM) (n-3), Hypertension (HTN) (n-1) constituted 2.1% 
and 0.7% of assessable survivors respectively. As majority were young patients .Even at 
follow up, median age was 39 years . Patients at follow up did not have DM and HTN 
.So contribution of these comorbitities is unlikely.
In our study total cumulative doses of doxorubicin >300 mg/m2 was associated with risk 
of cardiomyopathy.Total cumulative dose has been found regularly as a risk factor for 
development of cardiac dysfunction in previous studies in adults (4,7,9).
Length  of  follow  up  (5-16  years)  is  a  risk  factor  of  doxorubicin  –induced 
cardiomyopathy in our study. Majority of the patients treated were young at the time of 
diagnosis.  So, it  is important to have continued & prolonged follow up to know the 
incidence of cardiotoxicity. Steinherz et al(3) Thirty Eight percent of patients  followed 
up for 10 years  versus Eighteen percent of patients evaluated after less than 10 years 
had abnormal findings ..
In our series, only 15 patients received mediastinal radiotherapy with dose ranging from 
3000-4000cGy  &  showed  suggestive  significance  for  doxorubicin  –induced 
cardiomyopathy.  Dose  of  adriamycin  was  between  210-300  mg/m2   .Previous 
radiotherapy  to  the  mediastinum  has  been  described  as  a  risk  factor  (11,25).  Since 
cardiomyopathy in our study was seen in patients receiving anthracycline dose of >400 
mg /m2, mediastinal radiation has contributed to cardiac toxicity in our subset of patients 
who received doxorubicin dose in range of 210-300 mg/m2.
Comparative studies
Parameter CIA(2008)
MSKCC-
NY(1991)(3)
France(2003)(133)
No of patients 141 201 141
Cardiotoxicity % 24.1% 23% 27.6%
Risk factors for 
late cardiotoxicity
Old age
Female sex
Total 
Cumulative 
Total 
cumulative 
doses
Length of 
Male sex
Old age
Total cumulative 
doses
doses
Length of 
Follow up
follow up
Mediastinal 
Radiation
Radiotherapy
Laurel J.Steinherz et al(3) analysed study   in which 201 patients  were evaluated by 
echocardiogram from 4-20 years  after completion of anthracyclines with prospective 
and retrospective analysis .Twenty three percent (47/201)had abnormal cardiac function 
on non-invasive testing at long term follow up. Correlation between total cumulative 
dose ,length of  follow  up and mediastinal irradiation with incidence of abnormalities 
was significant. Fifty –six patients were followed up for 10 years or more (median 12 
years ), with a median anthracycline dose of 495 mg/m2.Thirty eight percent (21/56) of 
these patients ,compared with 18% (26/145) of patients evaluated after less than 10 years 
had abnormal findings Sixty three percent of patients followed up to 10 years or more 
after receiving 500 mg/m2 or more of anthracycline had abnormal findings. Nine of 201 
patients  had  late  symptoms,  including  cardiac  failure  and  dysarrhythmia  and  three 
patients died suddenly.
O  Hequet  et  al  (133)  analysed  a  group  of  patients  (141)  who  previously  received 
doxorubicin – based chemotherapy for lymphoma. Of 141 assessable patients, median 
age 54 years, median cumulative dose 300 mg/m2, only one developed congestive heart 
failure. Criteria for subclinical cardiomyopathy were found in 39 patients. Risk factors 
that  contributed  to  decreased  FS  were  male  sex,  older  age  (>50  years),  higher 
cumulative dose (>300 mg/m2) and radiotherapy. 
                                            CONCLUSION
1. Cardiac  abnormalities  can  occur  in  patients  treated  with  doxorubicin  for 
lymphoma in the absence of  CHF,  even who received moderate  anthracycline 
doses (210-300 mg/m2).
2. Older age (>50 yrs), female sex, higher cumulative dose of doxorubicin (>300 
mg/m2), length of follow up (12-16 years). Mediastinal radiotherapy were risk 
factor for development of late anthracycline cardiomyopathy.
3. Significant incidence of abnormal cardiac function (24.1%) on long term follow 
up demonstrated by non invasive monitoring calls for continued follow up and 
appropriate evaluation.
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PROFORMA – HL/NHL
Name - Age / Sex – s/no
Date of Diagnosis – 
Diagnosis - Stage - IPI/IPSS –
Symptoms
B symptoms Y/N
Chest pain Y/N
Abdomen pain Y/N
Bone pain Y/N
Head ache/seizures/FND Y/N
Comorbidities
HTN Y/N IHD Y/N
DM Y/N others Y/N
Signs
PS
Bulky site Y/N
LNE Y/N if yes C /A /I /Mediastinal /Abd
Hepatomegaly Y/N
Splenomegaly Y/N
Extranodal site Y/N if yes specify____________
Investigations
Hemogram N/Abn if Abn specify  _______________-
RFT N/Abn
LFT N/Abn
CECT chest/CXR N/Abn abn specify ______________
CECT abd/USG N/abd Abn specify ________________
ECG N/Abn Abn specify _______________
Echo N/Abn
Abn specify LVDD
LVSD __________
Chamber size ___________
RWMA __________
Wall thinning ________
EF%
Chemotherapy
Type – Hybrid/ABVD/CHOP/R-CHOP
No of cycles  4/6/8
Anthracycline cumulative dose – 
Mode of anthracycline administration     Bolus/IV
Concurrent cardiotoxic drugs  Y/N
RT
Site – C/Ax/Inguinal/Mediastinal/Abdomen
Dose
Response evaluation
CR/PR/PD if PR specify _________________
PD  Specify ______________
Relapse
HPE –
Stage – 
DFS – 
B symptoms Y/N
Salvage chemo Y/N
No of cycles
Response CR/PR/PD if PR specify _____________
PD specify_____________
Transplantation Indication
Conditioning regimen
Source of stem cells
Myelorecovery
Status at completion of Rx _________
Status at last F/U ____________
Date of last F/U _________
No of yrs of F/U
Cardiac evaluation (5 yrs)
Symptoms Y/N
Signs Y/N
ECG
ECHO
MUGA
Upfront 4 cycles 6 cycles 8 cycles 5yrs of F/U
ECG
ECHO
MUGA
